 |
MAP Pharmaceuticals Presents Analyses Showing LEVADEX Effective when Administered at Various Times in Migraine Cycle and in Patients with Concomitant Asthma
Jun 23, 2010
|
10.5 KB |
|
| |
MOUNTAIN VIEW, Calif., June 23, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, Ju...
|
|
MAP Pharmaceuticals to Present Two New Data Analyses from LEVADEX FREEDOM-301 Trial at AHS Annual Meeting
Jun 10, 2010
|
9.1 KB |
|
| |
MOUNTAIN VIEW, Calif., June 10, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific...
|
|
MAP Pharmaceuticals Provides Update on Progress of LEVADEX Development Program
May 11, 2010
|
11.7 KB |
|
| |
MOUNTAIN VIEW, Calif., May 11, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on its development program for LEVADEX(TM) orally inhaled migraine therapy. LEVADEX has completed Phase 3 efficacy development for the acute treatment of migraine.
"We continue to make good progress with our...
|
|
MAP Pharmaceuticals Reports First Quarter of 2010 Financial Results
May 4, 2010
|
11.9 KB |
|
| |
MOUNTAIN VIEW, Calif., May 4, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2010.
The net loss for the first quarter ended March 31, 2010 was $14.1 million compared to $9.9 million during the same period in 2009. MAP Pharmaceuticals had ...
|
|
MAP Pharmaceuticals to Present at Upcoming Healthcare Conferences
Apr 27, 2010
|
6.9 KB |
|
| |
MOUNTAIN VIEW, Calif., April 27, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor events in May:
35th Annual Deutsche Bank Health Care Conference
Tuesday, May 4, at 2:10 p.m. ET in Boston
Bank of America Merrill Ly...
|
|
MAP Pharmaceuticals Announces Potential of LEVADEX(TM) to Treat Patients with Menstrual Migraine and With Allodynia During Migraine
Apr 14, 2010
|
12.5 KB |
|
| |
MOUNTAIN VIEW, Calif., April 14, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced additional post-hoc analyses of data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy showing efficacy in two difficult to treat patient subpopulations, menstrual...
|
|
MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacodynamics Trial
Apr 7, 2010
|
10.7 KB |
|
| |
MOUNTAIN VIEW, Calif., April 7, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX(TM) orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery p...
|
|
MAP Pharmaceuticals to Report Additional Subpopulation Data From FREEDOM-301 Trial at the Annual Meeting of the American Academy of Neurology
Apr 7, 2010
|
9.4 KB |
|
| |
MOUNTAIN VIEW, Calif., April 7, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy in two patient subpopulations that are often difficult to tr...
|
|
MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results
Mar 2, 2010
|
15.5 KB |
|
| |
MOUNTAIN VIEW, Calif., March 2, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2009.
The net loss for the fourth quarter ended December 31, 2009 was $13.4 million compared to $21.8 million during the same period in 2008. The ...
|
|
MAP Pharmaceuticals to Present at Upcoming Healthcare Conferences
Feb 23, 2010
|
7.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 23, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following events in March:
RBC Capital Markets 2010 Healthcare Conference
Panel: Specialty Pharma - Adapting a Changing Business Model
Tuesday, March 2, a...
|
|
MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial
Feb 16, 2010
|
10.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 16, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and n...
|
|
MAP Pharmaceuticals Announces FDA will not Require a Second Pivotal Efficacy Study for LEVADEX(TM) NDA Submission
Jan 11, 2010
|
11.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatme...
|
|
MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Jan 6, 2010
|
6.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the 28th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2010 at 9:00 a.m. PT in San Francisco.
A live webcast of the presentation will be available on the Investor...
|
|
MAP Pharmaceuticals Appoints Alan Petro Vice President, Manufacturing and Technical Operations
Dec 1, 2009
|
10.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Alan Petro to the newly created position of Vice President, Manufacturing and Technical Operations. In his new role, Mr. Petro will lead the company's efforts in the area of product/proces...
|
|
MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility
Nov 12, 2009
|
10.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has secured a committed equity financing facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity Ltd. MAP Pharmaceuticals is not obligated to utilize...
|
|
MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Nov 11, 2009
|
6.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009 at 9:00 a.m. ET in New York City.
A live webcast of the presentation will be avai...
|
|
MAP Pharmaceuticals Reports Third Quarter of 2009 Financial Results
Nov 5, 2009
|
14.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2009.
Net income for the quarter ended September 30, 2009 was $19.3 million, compared to a net loss of $20.4 million during the same period in 200...
|
|
MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
Oct 29, 2009
|
10.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.
...
|
|
'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile
Sep 22, 2009
|
10.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced publication of results from an in vitro study of its novel LEVADEX(TM) (MAP0004) orally inhaled migraine therapy in development exploring the potential mechanism by which the pharmacokinetics (PK) and pharm...
|
|
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Sep 10, 2009
|
14.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX(TM) orally inhaled migraine therapy, currently in development, at the 14th Congress of the Int...
|
|
|
